Lupin Ltd Q1 FY27 Results — Earnings Call Analysis
Published 3 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.0L Cr
- Lupin expects high single-digit revenue growth in FY27. - Lupin expects high single-digit revenue growth in FY27, with EBITDA margins around 25%, despite competitive pressures and geopolitical uncertainties.
From Lupin Ltd's Q4 FY26 earnings-call transcript · updated 3 Jul 2026.
Price
₹2,368
Market Cap
₹1.0L Cr
P/E Ratio
18.1
Revenue Rank
Margin Rank
How does Lupin Ltd rank in Pharmaceuticals & Biotechnology?
Compare Lupin Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Lupin Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹7.5K Cr, net profit ₹1.5K Cr.
Full financials →📊 Revenue & Sales Performance
Rank 4- →Lupin expects high single-digit revenue growth in FY27.
- →US business projected to sustain over USD 1 billion revenue in FY27 despite some erosion from competition.
- →Biosimilar franchise revenues anticipated to multiply significantly within the year.
- →The India prescription business plans 20 product launches in FY27, with a history of outperforming IPM growth by ~1.2x-1.3x.
- →Emerging Markets to maintain strong growth momentum (35.2% YoY last year), led by Brazil and South Africa.
- →Other Developed Markets set for growth through new complex product rollouts and VISUfarma acquisition expansion.
- →Biosimilars and specialty portfolios (including injectables and respiratory products) are key growth drivers.
- →Expect to launch 50+ products in the US over three years, including 4 biosimilars and 2-3 505(b)(2) products.
- →VISUfarma Europe's ophthalmology business expected to grow double digit, crossing USD 100 million in 2-3 years.
See what Lupin Ltd said on profitability & margins — free account, 30 seconds.
🏗️ Capital Expenditure Plans
Yes- →Lupin is focused on strategic capital allocation primarily towards specialty assets in Developed Markets, including acquisitions like VISUfarma.
- →The company continues to seek assets in specialty segments such as ophthalmology, pulmonology, and rare neurology.
- →Post VISUfarma acquisition, there is a high flow of ophthalmology assets being evaluated.
- →Capital allocation aims at assets that complement Lupin's existing portfolios in India and specialty businesses.
- →Lupin remains cautious, deploying capital effectively based on risk-return criteria.
- →No explicit large future capex figures mentioned, but focus is on specialty business expansion and new product pipelines (biosimilars, injectables, respiratory).
- →Investment in R&D expected around 8% of sales going forward, emphasizing innovation.
- →Operating Working Capital stands at INR 7,132 crores (87 days), with net cash improving significantly (INR 4,636 crores).
See what Lupin Ltd said on fundraising & capital structure — free account, 30 seconds.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
What Lupin's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Lupin Ltd Q1 FY27 results?
- Lupin expects high single-digit revenue growth in FY27. - Lupin expects high single-digit revenue growth in FY27, with EBITDA margins around 25%, despite competitive pressures and geopolitical uncertainties.
What is Lupin Ltd share price analysis?
Lupin Ltd currently shows a neutral. The stock trades at a P/E of 18.1 with a market cap of ₹104,071. Investors should review the full earnings analysis for detailed insights.
Is Lupin Ltd planning capital expenditure?
- Lupin is focused on strategic capital allocation primarily towards specialty assets in Developed Markets, including acquisitions like VISUfarma.
Keep Lupin Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.